> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Clears Cepheid Xpert Carba-R Test
- URL: https://www.fdaweb.com/fda-clears-cepheid-xpert-carba-r-test/
- Published: 2016-03-09T12:00:00.000Z
- Updated: 2026-09-15T02:42:09.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5135018

> FDA has cleared a Cepheid 510(k) for the Xpert Carba-R, an in vitro diagnostic test for identifying distinct families of carbapenem resistance genes that together represent the most common carbapenemases identified globally, including KPC, NDM, VIM, OXA-48 and IMP. “The emergence of carbapenemase producing organisms, known as CPOs, represents a significant global healthcare risk since these bacteria are resistant to many of the beta-lactam antibiotics used for empiric therapy for gram negative infections,” the company says. “These resistance genes are highly transmissible from one bacterial species to another, leading to well-documented outbreaks associated with high morbidity and mortality.” The molecular test uses a bacterial isolate to deliver a result in under an hour. The Xpert Carba-R is the 20th IVD test available to run on Cepheid’s GeneXpert System.